mTOR inhibitor-related pulmonary toxicity; incidence even higher

By Willemsen Anna E. C. A. B.   van Herpen Carla M. L.  

Acta Oncologica, Vol. 52, Iss. 6, 2013-08 ,pp. : 1234-1234

Informa Healthcare

Access to resources Recommend Favorite

Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials

By Iacovelli Roberto   Palazzo Antonella   Mezi Silvia   Morano Federica   Naso Giuseppe   Cortesi Enrico  

Acta Oncologica, Vol. 51, Iss. 7, 2012-09 ,pp. : 873-879

Informa Healthcare

Access to resources Recommend Favorite

Role of mTOR inhibitor in cholangiocarcinoma cell progression

By        

Oncology Letters, Vol. 7, Iss. 3, 2014-01 ,pp. : 854-860

Spandidos Publications

Access to resources Recommend Favorite

Mechanisms of mTOR inhibitor resistance in cancer therapy

By Carew Jennifer  

Targeted Oncology, Vol. 6, Iss. 1, 2011-03 ,pp. : 17-27

Springer Publishing Company

Access to resources Recommend Favorite

Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases

By Ladoire Sylvain   Beynat Caroline   Diaz Pierre   Coudert Bruno   Favier Laure   Ghiringhelli François  

Medical Oncology, Vol. 27, Iss. 3, 2010-09 ,pp. : 938-941

Humana Press, Inc

Access to resources Recommend Favorite